Background and goal: This study examined whether patients with non-reversible chronic airway disease using a transparent capsule in single-dose dry powder inhalers affects the amount of medication ...
Background and Goal: This study examined whether patients with non-reversible chronic airway disease using a transparent capsule in single-dose dry powder inhalers affects the amount of medication ...
EQT Life Sciences is pleased to announce that the LSP 7 Fund has invested in Kinaset Therapeutics (the "Company"), a clinical-stage biopharmaceutical company based in Boston, U.S. developing a novel ...
Proceeds to advance frevecitinib, an inhaled pan-JAK inhibitor with the potential to treat the broad severe asthma population, through Phase 2 studies ...
TipRanks on MSN
CSPC wins China trial green light for first inhaled nintedanib for pulmonary fibrosis
CSPC Pharmaceutical Group ( ($HK:1093) ) has issued an announcement. CSPC Pharmaceutical Group has received approval from China’s National Medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results